Yunding Xinyao (01952) announced today that the summary meeting of the "Clinical Application Comprehensive Evaluation Project of Iralin" initiated and hosted by the National Health Commission's Expert Committee on Clinical Application and Resistance Evaluation of Antimicrobial Drugs was held in peking, and the final project report was released.
Zhitong Finance APP learned that Yunding Xinyao (01952) announced today that the summary meeting of the "Clinical Application Comprehensive Evaluation Project of Iralin" initiated and hosted by the National Health Commission's Expert Committee on Clinical Application and Resistance Evaluation of Antimicrobial Drugs was held in peking, and the final project report was released.
The project aims to conduct a comprehensive clinical evaluation of the use of new antimicrobial drugs in infection treatment in China, further promoting the rational use of newly listed antimicrobial drugs in clinical applications, providing data support for the government to formulate relevant policies, and better serving patients. Iralin has shown good efficacy and safety in treating 3,369 infected patients from various departments such as ICU, hematology, transplantation, and respiratory, especially in patients with pulmonary infections caused by various pathogens such as carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae. The final report indicates an overall effective rate of 91.1% after 3 days of treatment with Iralin, and a total treatment effective rate of 90.1% at the end of the treatment.
